NeuroSense Therapeutics Ltd - Warrants (09/11/2026)
NRSNW
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.26M
Close$
$-0.00
100.1% downside
Current Fair Value
100.1% downsideOvervalued by 100.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.26 Million |
|---|---|
| Enterprise Value | $20.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.44 |
| Beta | 1.58 |
| Outstanding Shares | 25,402,000 |
Return
| Return on Equity | 555.00% |
|---|---|
| Return on Assets | -842.22% |
| Return on Invested Capital | 575.94% |
Valuation & Multiples
| P/E Ratio | -3.21 |
|---|---|
| PEG | -1.83 |
| Price to Sales | - |
| Price to Book Ratio | -0.19 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.36 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 31, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
June 22, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$514,100
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.65%▼ 0.00% |
|---|---|
| Total Invested | $32,821▼ 42.11% |
| Investors Holding | 30% |
ESG Score
No data